Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Conjugate pneumococcal vaccines: an overview.

E K Mulholland¹

¹Department of Paediatrics, University of Melbourne, VIC. mulhollk@cryptic.rch.unimelb.edu.au

The Medical Journal of Australia

|November 4, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme.

The Lancet. Microbe·2024

Same author

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.

International journal of pediatric otorhinolaryngology·2023

Same author

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji.

The Lancet regional health. Western Pacific·2022

Same author

Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.

Vaccine·2021

Same author

Hospital surveillance predicts community pneumococcal antibiotic resistance in Vietnam.

The Journal of antimicrobial chemotherapy·2020

Same author

Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys: a study protocol for a prospective observational study and lessons learned.

BMC public health·2019

A seven-valent pneumococcal conjugate vaccine effectively prevents invasive pneumococcal disease in infants. Ongoing research explores global vaccine development and potential serotype replacement, while also noting reduced antimicrobial resistance.

Area of Science:

* Vaccinology and Infectious Diseases
* Public Health and Epidemiology

Background:

* The seven-valent pneumococcal conjugate vaccine (PCV7) demonstrated significant efficacy against invasive pneumococcal disease (IPD).
* PCV7 showed lesser efficacy against otitis media and pneumonia, highlighting the need for broader serotype coverage.
* Licensed in the US in 2000, PCV7 is recommended for routine infant immunization and catch-up vaccination in high-risk children.

Purpose of the Study:

* To review the efficacy and impact of the seven-valent conjugate pneumococcal vaccine.
* To discuss the development of broader-valent vaccines for global use.
* To address challenges and considerations for vaccine introduction in developing countries.

Main Methods:

* Review of clinical trial data and epidemiological studies on pneumococcal conjugate vaccines.

Related Experiment Videos

* Analysis of vaccine effectiveness, serotype distribution, and antimicrobial resistance patterns.

* Consideration of global vaccine development and implementation strategies.

Main Results:

* Dramatic efficacy of PCV7 against invasive pneumococcal disease was confirmed.
* Evidence of serotype replacement in vaccine recipients was observed, potentially impacting long-term effectiveness.
* Vaccine introduction may lead to reduced rates of antimicrobial resistance in pneumococci.

Conclusions:

* The seven-valent pneumococcal conjugate vaccine is highly effective against IPD.
* Development of 9- and 11-valent vaccines is underway for broader global impact.
* Addressing the cost and implementation challenges is crucial for developing countries to benefit from these vaccines.